| GRAIL INC. DL-,01 |
| USA |
| Gesundheit |
| US3847471014 / A40F8M |
| NL0 (Frankfurt) / GRAL (NASDAQ) |
| FRA:NL0, ETR:NL0, NL0:GR, NASDAQ:GRAL |
| - |
| https://grail.com/ |
|
Grail Inc. is a biotechnology company focused on the innovative field of early cancer detection testing. Its primary function is to develop and commercialize blood tests that enable the early detectio..
>Volltext.. |
| 1769.48 Mio. EUR |
| 1040.35 Mio. EUR |
| 126.93 Mio. EUR |
| -326.85 Mio. EUR |
| -352.19 Mio. EUR |
| -9.64 EUR |
| 47.32 Mio. EUR |
| 215.38 Mio. EUR |
| -257.89 Mio. EUR |
| 11.35 |
| 3.28% |
| 82.24% |
| - |
| - |
| - |
| GRAIL INC, GRAIL INCORPORATED, NASDAQ:GRAL |
| 04.03.26 |